Celgene discovers, develops and commercializes innovative therapies to treat cancer and immune-inflammatory-related diseases.

Company Overview

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey and was founded in 1986 by Robert Harris and Sol Barer. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank.

There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), pancreatic cancer, non-small lung cancer, and melanoma.


  • In 1986, Robert Hariri and Sol Barer founded Celgene, originally a unit of the Celanese Corporation. It was spun off as an independent company following the merger of Celanese Corporation with American Hoechst Corporation.
  • In August 2000, Celgene acquired Signal Pharmaceuticals, Inc.
  • In December 2002, Celgene acquired Anthrogenesis. In March 2008, Celgene closed its $2.9 billion acquisition of Pharmion Corporation.
  • In December 2009, Celgene announced the acquisition of Gloucester Pharmaceuticals.
  • In June 2010 Celgene Corporation and Abraxis BioScience Inc. jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience.
  • In January 2012, Celgene and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc.
  • In 2014, Celgene and OncoMed Pharmaceuticals entered into a cancer stem cell therapeutic development agreement encompassing Demcizumab and five other biologics from OncoMed's pipeline.
  • Also in 2014, Sutro Biopharma entered into a strategic collaboration and option agreement with Celgene Corporation to discover and develop multispecific antibodies and antibody drug conjugates (ADCs).
  • In April 2015, Celgene announced it would commence a collaboration with Astrazeneca, worth $450 million.
  • In June 2015 Celgene announced it had licensed Lyceras RORgamma agonist portfolio for up to $105 million.
  • In July 2015, the company announced it would acquire Receptos for $7.2 billion in a move to strengthen the company's inflammation and immunology areas.
  • In May 2016, the company announced it would launch a partnership with Agios Pharmaceuticals, developing metabolic immuno-oncology therapies.
  • In October, the company acquired EngMab AG for $600 million.
  • In January 2017, the company announced it would acquire Delinia for $775 million, increasing the company's autoimmune disease therapy offerings.
  • In January 2018, Celgene announced it would acquire Impact Biomedicines for $7 billion. In the same month, the company announced it would acquire Juno Therapeutics for $9 billion.

Celgene Corporation discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; and EXSCIENTIA LTD.


Celgene has acquired 14 organizations. One of their acquisitions was Juno Therapeutics on Jan 22, 2018. They acquired Juno Therapeutics for $9B. The intellectual property of Celgene includes 585 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category. Additionally, Celgene has registered 342 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products'. Celgene has made 55 investments. One of their investments was on Feb 7, 2019, when they invested $60.8M in HiberCell.


January 3, 2019
In the first major pharmaceutical deal of the year, Bristol-Myers Squibb said on Thursday that it would buy Celgene, which makes cancer drugs, in a cash-and-stock deal valued at $74 billion.
January 2019
Celgene agrees to pay up to $7 billion for the biotechnology company Impact Biomedicines, to enter market for blood-disease drugs.
Celgene agrees to pay $280 million to settle claims that it marketed Thalomid and Revlimid for unapproved uses.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Celgene funding round, February 2012
February 9, 2012
February 22, 2011
3 Results
Results per page:
Page 1 of 1



Further reading


Documentaries, videos and podcasts





Ben Adams
January 15, 2021
A year after Eli Lilly abruptly pulled out of an R&D pact with NextCure and its CMO left after weak trials results, the biotech is shoring up its research team with the addition of ex-Celgene exec Han Myint, M.D..
Nick Paul
January 5, 2021
Ikena Oncology has raised $120 million to advance its expanding pipeline of cancer drugs. The series B round comes as Ikena prepares to add a TEAD inhibitor to its roster of clinical programs and hustles a first-in-class KRAS asset through lead optimization.
Scopus BioPharma Inc.
December 29, 2020
/PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the appointment of additional members to its Board of Directors. Scopus is a...
November 24, 2020
Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), today announced Dr. Alex Lugovskoy has joined the Company as Chief Operating Officer, and that the Company has strengthened its Scientific Advisory Board with the addition of leading drug developer and clinician Dr. Rob Hershberg.
Dragonfly Therapeutics, Inc.
November 24, 2020
/PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), today announced Dr. Alex Lugovskoy has joined the Company as Chief Operating...
Mark Terry
November 9, 2020
Here's a look at some of the upcoming target action dates on the U.S. FDA's calendar.
November 9, 2020
Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis - read this article along with other careers information, tips and advice on BioSpace
Heather McKenzie
November 6, 2020
Setbacks and delays caused by COVID-19 are making everyone, in every facet of life, nervous. This week, that includes legacy Celgene CVR investors who are staging a mass exodus as two drugs under the agreement near the deadline and one, Liso-cel, faces inspection delays.
November 4, 2020
Arcutis Biotherapeutics, Inc. announced that Terrie Curran has been appointed to the Arcutis Board of Directors effective Nov. 2, 2020, and that Alexander Asam, Ph.D. has decided to step down from the Board.
Robert King
September 30, 2020
House Democrats slammed drug companies Teva and Celgene for consistent price hikes on vital drugs during a hearing Wednesday.
Press Trust of India
July 10, 2020
Lenalidomide drug is used to treat various types of cancers by slowing or stopping the growth of aberrant cells
Amirah Al Idrus
June 25, 2020
Bristol Myers Squibb upped its forecast of annual sales from its late-stage pipeline from $15 billion to $20 billion, starting in the second half of the decade. Those sales will be led by products picked up in its $74 billion Celgene buyout.
Nick Paul
June 18, 2020
Bristol Myers Squibb is continuing a drug discovery collaboration with Ubiquigent that it inherited in its merger with Celgene. The Big Pharma recently scrapped an alliance with Jounce Therapeutics that was formed by Celgene but is sticking with deubiquitinase (DUB) enzyme specialist Ubiquigent.
Ben Adams
June 5, 2020
After culling a $2.6 billion biobucks pact last year, Bristol Myers Squibb is making a second and final cut to its pact with I-O biotech Jounce Therapeutics.
June 1, 2020
Biond Biologics Ltd. ("Biond" or the "Company"), a privately-held biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, today announced the appointment of Jerome ("Jerry") Zeldis, M.D., Ph.D. to its Board of Directors.
May 15, 2020
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma - read this article along with other careers information, tips and advice on BioSpace
Alex Keown
May 13, 2020
This morning, the companies announced the regulatory agency issued a Refusal to File letter regarding the BLA for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pretreated relapsed and refractory multiple myeloma.
May 11, 2020
Bristol Myers Squibb Research at ASCO Demonstrates Diverse Approaches in Treating Cancer to Improve Outcomes for Patients - read this article along with other careers information, tips and advice on BioSpace
Reuters Editorial
May 6, 2020
Bristol Myers Squibb Co said on Wednesday the U.S. FDA has decided to extend the approval timeline for the drugmaker's experimental blood cancer therapy that was acquired as part of the $74 billion buyout of Celgene.
Ap Mcclatchy
April 21, 2020
Boston Herald
Things have gone from bad to worse for Brian Helstien. For a decade, he's been grappling with multiple myeloma, a form of blood cancer. Now he needs surgery for a leaky heart valve.


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.